TY - JOUR
T1 - Cataract surgery and nonsteroidal antiinflammatory drugs
AU - Hoffman, Richard S.
AU - Braga-Mele, Rosa
AU - Donaldson, Kendall
AU - Emerick, Geoffrey
AU - Henderson, Bonnie
AU - Kahook, Malik
AU - Mamalis, Nick
AU - Miller, Kevin M.
AU - Realini, Tony
AU - Shorstein, Neal H.
AU - Stiverson, Richard K.
AU - Wirostko, Barbara
N1 - Publisher Copyright:
© 2016 ASCRS and ESCRS
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Nonsteroidal antiinflammatory drugs (NSAIDs) have become an important adjunctive tool for surgeons performing routine and complicated cataract surgery. These medications have been found to reduce pain, prevent intraoperative miosis, modulate postoperative inflammation, and reduce the incidence of cystoid macular edema (CME). Whether used alone, synergistically with steroids, or for specific high-risk eyes prone to the development of CME, the effectiveness of these medications is compelling. This review describes the potential preoperative, intraoperative, and postoperative uses of NSAIDs, including the potency, indications and treatment paradigms and adverse effects and contraindications. A thorough understanding of these issues will help surgeons maximize the therapeutic benefits of these agents and improve surgical outcomes. Financial Disclosure Proprietary or commercial disclosures are listed after the references.
AB - Nonsteroidal antiinflammatory drugs (NSAIDs) have become an important adjunctive tool for surgeons performing routine and complicated cataract surgery. These medications have been found to reduce pain, prevent intraoperative miosis, modulate postoperative inflammation, and reduce the incidence of cystoid macular edema (CME). Whether used alone, synergistically with steroids, or for specific high-risk eyes prone to the development of CME, the effectiveness of these medications is compelling. This review describes the potential preoperative, intraoperative, and postoperative uses of NSAIDs, including the potency, indications and treatment paradigms and adverse effects and contraindications. A thorough understanding of these issues will help surgeons maximize the therapeutic benefits of these agents and improve surgical outcomes. Financial Disclosure Proprietary or commercial disclosures are listed after the references.
UR - http://www.scopus.com/inward/record.url?scp=84992397285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992397285&partnerID=8YFLogxK
U2 - 10.1016/j.jcrs.2016.06.006
DO - 10.1016/j.jcrs.2016.06.006
M3 - Review article
C2 - 27697257
AN - SCOPUS:84992397285
VL - 42
SP - 1368
EP - 1379
JO - Journal of Cataract and Refractive Surgery
JF - Journal of Cataract and Refractive Surgery
SN - 0886-3350
IS - 9
ER -